Georgetown University AP4 Center Plan

乔治城大学 AP4 中心规划

• 批准号: 6830482
• 负责人: ANATOLY DRITSCHILO
• 金额: $ 7.76万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-01 至 2006-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6830482
• 关键词: biomedical facility; cooperative study; health science research; neoplasm /cancer; neoplasm /cancer radiation therapy; oncology; radiosensitizer

DESCRIPTION (provided by applicant): Georgetown University (GU) has supported a successful NIH/NCI funded multidisciplinary program in cancer treatment research for the past 20 years, integrating medical oncology, surgery and radiation oncology within the Lombardi Comprehensive Cancer Center (LCCC). A novel aspect of this research has been focused on developing radiation sensitizing strategies. Molecular targets for radiation sensitization (and chemosensitization) of cancers have been recognized as a significant new area for drug development research, with potential for improving local tumor control, lower treatment-related morbidities and enhanced therapeutic ratio. Furthermore, industry interest has focused on the potential market for such agents, estimated to be in excess of $10 billion annually. In this planning grant application, institutional commitment of personnel, space and shared resources, as well as commitments by two industrial partners (a medical device manufacturer and a biotechnology company) of financial support will provide the initial critical structure for this program. In the performance of the aims in this application, a third partner will be identified, a partner meeting will be planned and scheduled, strategic planning, patent and publication policies will be developed. Successful competition and completion of the aims of this planning application will allow for the next step in AP4 center development.

描述(由申请人提供)： 乔治敦大学(GU)在过去20年里支持了NIH/NCI资助的癌症治疗研究的多学科项目，在伦巴迪综合癌症中心(LCCC)内整合了内科肿瘤学、外科和放射肿瘤学。这项研究的一个新方面一直集中在开发辐射增敏策略上。肿瘤放射增敏(和化疗增敏)的分子靶点已被认为是药物开发研究的一个重要新领域，具有改善局部肿瘤控制、降低治疗相关发病率和提高治愈率的潜力。此外，业界的兴趣集中在这类代理商的潜在市场上，估计每年超过100亿美元。 在这一规划赠款申请中，人员、空间和共享资源的机构承诺，以及两个工业合作伙伴(一家医疗设备制造商和一家生物技术公司)对资金支持的承诺，将为该计划提供初步的关键结构。在履行本申请中的目标时，将确定第三个合作伙伴，计划和安排合作伙伴会议，制定战略规划、专利和出版政策。本次规划申请的成功竞争和目标的完成将为AP4中心的下一步发展奠定基础。